Global Amyotrophic Lateral Sclerosis Therapeutics Market Growth 2019-2024

Published On: Jan 2019

Format: PDF

Publisher: LP Infomation

Pages: 137

Report ID: 224543

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

According to this study, over the next five years the Amyotrophic Lateral Sclerosis Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2017. In particular, this report presents the global market share (sales and revenue) of key companies in Amyotrophic Lateral Sclerosis Therapeutics business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis Therapeutics market by product type, application, key manufacturers and key regions and countries.

This study considers the Amyotrophic Lateral Sclerosis Therapeutics value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2013 to 2018, in Section 2.3; and forecast to 2024 in section 11.7.
Riluzole
Edaravone (Radicava)
Other
Segmentation by application: breakdown data from 2013 to 2018, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Drugs Store
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Amyotrophic Lateral Sclerosis Therapeutics consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2024.
To understand the structure of Amyotrophic Lateral Sclerosis Therapeutics market by identifying its various subsegments.
Focuses on the key global Amyotrophic Lateral Sclerosis Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyotrophic Lateral Sclerosis Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Amyotrophic Lateral Sclerosis Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Contents

2018-2023 Global Amyotrophic Lateral Sclerosis Therapeutics Consumption Market Report

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Amyotrophic Lateral Sclerosis Therapeutics Consumption 2013-2023
2.1.2 Amyotrophic Lateral Sclerosis Therapeutics Consumption CAGR by Region
2.2 Amyotrophic Lateral Sclerosis Therapeutics Segment by Type
2.2.1 Riluzole
2.2.2 Edaravone (Radicava)
2.2.3 Other
2.3 Amyotrophic Lateral Sclerosis Therapeutics Consumption by Type
2.3.1 Global Amyotrophic Lateral Sclerosis Therapeutics Consumption Market Share by Type (2013-2018)
2.3.2 Global Amyotrophic Lateral Sclerosis Therapeutics Revenue and Market Share by Type (2013-2018)
2.3.3 Global Amyotrophic Lateral Sclerosis Therapeutics Sale Price by Type (2013-2018)
2.4 Amyotrophic Lateral Sclerosis Therapeutics Segment by Application
2.4.1 Hospital
2.4.2 Drugs Store
2.4.3 Other
2.5 Amyotrophic Lateral Sclerosis Therapeutics Consumption by Application
2.5.1 Global Amyotrophic Lateral Sclerosis Therapeutics Consumption Market Share by Application (2013-2018)
2.5.2 Global Amyotrophic Lateral Sclerosis Therapeutics Value and Market Share by Application (2013-2018)
2.5.3 Global Amyotrophic Lateral Sclerosis Therapeutics Sale Price by Application (2013-2018)

3 Global Amyotrophic Lateral Sclerosis Therapeutics by Players
3.1 Global Amyotrophic Lateral Sclerosis Therapeutics Sales Market Share by Players
3.1.1 Global Amyotrophic Lateral Sclerosis Therapeutics Sales by Players (2016-2018)
3.1.2 Global Amyotrophic Lateral Sclerosis Therapeutics Sales Market Share by Players (2016-2018)
3.2 Global Amyotrophic Lateral Sclerosis Therapeutics Revenue Market Share by Players
3.2.1 Global Amyotrophic Lateral Sclerosis Therapeutics Revenue by Players (2016-2018)
3.2.2 Global Amyotrophic Lateral Sclerosis Therapeutics Revenue Market Share by Players (2016-2018)
3.3 Global Amyotrophic Lateral Sclerosis Therapeutics Sale Price by Players
3.4 Global Amyotrophic Lateral Sclerosis Therapeutics Manufacturing Base Distribution, Sales Area, Product Types by Players
3.4.1 Global Amyotrophic Lateral Sclerosis Therapeutics Manufacturing Base Distribution and Sales Area by Players
3.4.2 Players Amyotrophic Lateral Sclerosis Therapeutics Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Amyotrophic Lateral Sclerosis Therapeutics by Regions
4.1 Amyotrophic Lateral Sclerosis Therapeutics by Regions
4.1.1 Global Amyotrophic Lateral Sclerosis Therapeutics Consumption by Regions
4.1.2 Global Amyotrophic Lateral Sclerosis Therapeutics Value by Regions
4.2 Americas Amyotrophic Lateral Sclerosis Therapeutics Consumption Growth
4.3 APAC Amyotrophic Lateral Sclerosis Therapeutics Consumption Growth
4.4 Europe Amyotrophic Lateral Sclerosis Therapeutics Consumption Growth
4.5 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Consumption Growth

5 Americas
5.1 Americas Amyotrophic Lateral Sclerosis Therapeutics Consumption by Countries
5.1.1 Americas Amyotrophic Lateral Sclerosis Therapeutics Consumption by Countries (2013-2018)
5.1.2 Americas Amyotrophic Lateral Sclerosis Therapeutics Value by Countries (2013-2018)
5.2 Americas Amyotrophic Lateral Sclerosis Therapeutics Consumption by Type
5.3 Americas Amyotrophic Lateral Sclerosis Therapeutics Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Amyotrophic Lateral Sclerosis Therapeutics Consumption by Countries
6.1.1 APAC Amyotrophic Lateral Sclerosis Therapeutics Consumption by Countries (2013-2018)
6.1.2 APAC Amyotrophic Lateral Sclerosis Therapeutics Value by Countries (2013-2018)
6.2 APAC Amyotrophic Lateral Sclerosis Therapeutics Consumption by Type
6.3 APAC Amyotrophic Lateral Sclerosis Therapeutics Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis Therapeutics by Countries
7.1.1 Europe Amyotrophic Lateral Sclerosis Therapeutics Consumption by Countries (2013-2018)
7.1.2 Europe Amyotrophic Lateral Sclerosis Therapeutics Value by Countries (2013-2018)
7.2 Europe Amyotrophic Lateral Sclerosis Therapeutics Consumption by Type
7.3 Europe Amyotrophic Lateral Sclerosis Therapeutics Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics by Countries
8.1.1 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Consumption by Countries (2013-2018)
8.1.2 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Value by Countries (2013-2018)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Consumption by Type
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis Therapeutics Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.2 Amyotrophic Lateral Sclerosis Therapeutics Distributors
10.3 Amyotrophic Lateral Sclerosis Therapeutics Customer

11 Global Amyotrophic Lateral Sclerosis Therapeutics Market Forecast
11.1 Global Amyotrophic Lateral Sclerosis Therapeutics Consumption Forecast (2018-2023)
11.2 Global Amyotrophic Lateral Sclerosis Therapeutics Forecast by Regions
11.2.1 Global Amyotrophic Lateral Sclerosis Therapeutics Forecast by Regions (2018-2023)
11.2.2 Global Amyotrophic Lateral Sclerosis Therapeutics Value Forecast by Regions (2018-2023)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Amyotrophic Lateral Sclerosis Therapeutics Forecast by Type
11.8 Global Amyotrophic Lateral Sclerosis Therapeutics Forecast by Application

12 Key Players Analysis
12.1 Mitsubishi Tanabe Pharma
12.1.1 Company Details
12.1.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.1.4 Main Business Overview
12.1.5 Mitsubishi Tanabe Pharma News
12.2 Sanofi
12.2.1 Company Details
12.2.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.2.3 Sanofi Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.2.4 Main Business Overview
12.2.5 Sanofi News
12.3 Mylan Pharma
12.3.1 Company Details
12.3.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.3.4 Main Business Overview
12.3.5 Mylan Pharma News
12.4 Apotex
12.4.1 Company Details
12.4.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.4.3 Apotex Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.4.4 Main Business Overview
12.4.5 Apotex News
12.5 Glemark Generics
12.5.1 Company Details
12.5.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.5.3 Glemark Generics Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.5.4 Main Business Overview
12.5.5 Glemark Generics News
12.6 Covis Pharma
12.6.1 Company Details
12.6.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.6.3 Covis Pharma Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.6.4 Main Business Overview
12.6.5 Covis Pharma News
12.7 Sun Pharma
12.7.1 Company Details
12.7.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.7.3 Sun Pharma Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.7.4 Main Business Overview
12.7.5 Sun Pharma News
12.8 Lunan Pharma
12.8.1 Company Details
12.8.2 Amyotrophic Lateral Sclerosis Therapeutics Product Offered
12.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis Therapeutics Sales, Revenue, Price and Gross Margin (2016-2018)
12.8.4 Main Business Overview
12.8.5 Lunan Pharma News

13 Research Findings and Conclusion